Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22<sup>+</sup> acute lymphoblastic leukemia: results of the phase IB ITCC-059 trialEdoardo Pennesi, C. Michel Zwaan, Erica Brivio et al.|Haematologica|2024Cited by 18
Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059Jen-Hao Wu, Alwin D. R. Huitema, Edoardo Pennesi et al.|Clinical Pharmacokinetics|2024Cited by 6
Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and OutcomesErica Brivio, C. Michel Zwaan, Arnaud Petit et al.|Blood|2024Cited by 5
Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II TrialEdoardo Pennesi, C. Michel Zwaan, Erica Brivio et al.|Blood|2022Cited by 3
Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B TrialEdoardo Pennesi, C. Michel Zwaan, Erica Brivio et al.|Blood|2022Cited by 2